Tyra Biosciences Stock Performance
| TYRA Stock | USD 21.12 0.12 0.57% |
On a scale of 0 to 100, Tyra Biosciences holds a performance score of 17. The entity has a beta of 0.3, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Tyra Biosciences' returns are expected to increase less than the market. However, during the bear market, the loss of holding Tyra Biosciences is expected to be smaller as well. Please check Tyra Biosciences' expected short fall, and the relationship between the value at risk and daily balance of power , to make a quick decision on whether Tyra Biosciences' existing price patterns will revert.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Tyra Biosciences are ranked lower than 17 (%) of all global equities and portfolios over the last 90 days. Despite somewhat uncertain basic indicators, Tyra Biosciences sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.57 | Five Day Return 34.61 | Year To Date Return 46.36 | Ten Year Return (18.77) | All Time Return (18.77) |
1 | Acquisition by Alan Fuhrman of 701 shares of Tyra Biosciences at 9.129 subject to Rule 16b-3 | 09/15/2025 |
2 | Insider Trading | 10/10/2025 |
3 | Historical volatility pattern of Tyra Biosciences Inc. visualized - Market Activity Report Free Fast Gain Swing Trade Alerts - newser.com | 10/20/2025 |
4 | How Tyra Biosciences Inc. stock performs during Fed tightening cycles - 2025 Breakouts Breakdowns High Accuracy Swing Trade Signals - newser.com | 10/28/2025 |
5 | Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights | 11/05/2025 |
6 | Has Tyra Biosciences Inc. found a price floor - Dividend Hike Growth Oriented Trading Recommendations - newser.com | 11/12/2025 |
7 | Disposition of 1500 shares by Daniel Bensen of Tyra Biosciences at 17.0713 subject to Rule 16b-3 | 11/17/2025 |
8 | Disposition of 75633 shares by Daniel Bensen of Tyra Biosciences at 16.0727 subject to Rule 16b-3 | 11/18/2025 |
9 | Disposition of 49956 shares by Daniel Bensen of Tyra Biosciences at 16.3203 subject to Rule 16b-3 | 11/19/2025 |
10 | Tyra Biosciences Sets New 1-Year High - Heres What Happened - MarketBeat | 11/21/2025 |
| Begin Period Cash Flow | 59 M | |
| Total Cashflows From Investing Activities | -98.4 M |
Tyra Biosciences Relative Risk vs. Return Landscape
If you would invest 1,200 in Tyra Biosciences on August 25, 2025 and sell it today you would earn a total of 912.00 from holding Tyra Biosciences or generate 76.0% return on investment over 90 days. Tyra Biosciences is currently generating 0.9594% in daily expected returns and assumes 4.3638% risk (volatility on return distribution) over the 90 days horizon. In different words, 39% of stocks are less volatile than Tyra, and 81% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Tyra Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Tyra Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Tyra Biosciences, and traders can use it to determine the average amount a Tyra Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2198
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | TYRA | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.36 actual daily | 39 61% of assets are more volatile |
Expected Return
| 0.96 actual daily | 19 81% of assets have higher returns |
Risk-Adjusted Return
| 0.22 actual daily | 17 83% of assets perform better |
Based on monthly moving average Tyra Biosciences is performing at about 17% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Tyra Biosciences by adding it to a well-diversified portfolio.
Tyra Biosciences Fundamentals Growth
Tyra Stock prices reflect investors' perceptions of the future prospects and financial health of Tyra Biosciences, and Tyra Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Tyra Stock performance.
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.23 | ||||
| Current Valuation | 858.21 M | ||||
| Shares Outstanding | 53.37 M | ||||
| Price To Earning | (3.33) X | ||||
| Price To Book | 4.02 X | ||||
| EBITDA | (103.66 M) | ||||
| Net Income | (86.48 M) | ||||
| Cash And Equivalents | 275.11 M | ||||
| Cash Per Share | 6.61 X | ||||
| Total Debt | 6.22 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 50.83 X | ||||
| Book Value Per Share | 5.26 X | ||||
| Cash Flow From Operations | (69.77 M) | ||||
| Earnings Per Share | (1.88) X | ||||
| Market Capitalization | 1.13 B | ||||
| Total Asset | 363.56 M | ||||
| Retained Earnings | (251.31 M) | ||||
| Working Capital | 332.87 M | ||||
About Tyra Biosciences Performance
By analyzing Tyra Biosciences' fundamental ratios, stakeholders can gain valuable insights into Tyra Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Tyra Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Tyra Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.24) | (0.25) | |
| Return On Capital Employed | (0.30) | (0.31) | |
| Return On Assets | (0.24) | (0.25) | |
| Return On Equity | (0.25) | (0.24) |
Things to note about Tyra Biosciences performance evaluation
Checking the ongoing alerts about Tyra Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Tyra Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Tyra Biosciences appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (86.48 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Tyra Biosciences currently holds about 275.11 M in cash with (69.77 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.61. | |
| Tyra Biosciences has a frail financial position based on the latest SEC disclosures | |
| Over 97.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Tyra Biosciences Sets New 1-Year High - Heres What Happened - MarketBeat |
- Analyzing Tyra Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Tyra Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Tyra Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Tyra Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Tyra Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Tyra Biosciences' stock. These opinions can provide insight into Tyra Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Tyra Stock analysis
When running Tyra Biosciences' price analysis, check to measure Tyra Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tyra Biosciences is operating at the current time. Most of Tyra Biosciences' value examination focuses on studying past and present price action to predict the probability of Tyra Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tyra Biosciences' price. Additionally, you may evaluate how the addition of Tyra Biosciences to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |